Efficacy of sofosbuvir and ribavirin therapy in patients with genotype 2 hepatitis C virus: Significance of variants associated with resistance in NS3, NS5A and NS5B regio
Not Applicable
Completed
- Conditions
- the patients infected with genotype 2 HCV who received combination therapy with sofosbvir and rivabirin.
- Registration Number
- JPRN-UMIN000018089
- Lead Sponsor
- Department of Gastroenterology & Hepatology, Saitama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
the patients infected with HCV other than genotype 2
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the efficacy of antiviral therapy at end of treatment and 4 week after.
- Secondary Outcome Measures
Name Time Method